Lilly(US:LLY) 智通财经网·2026-01-07 15:09Core Viewpoint - The obesity drug sector is experiencing a surge, with notable stock increases for companies like Eli Lilly, Amgen, Novo Nordisk, and Pfizer, driven by strategic acquisitions and positive market sentiment [1] Company Developments - Eli Lilly (LLY.US) shares rose over 4%, reaching a historical high, as the company is nearing a deal to acquire Ventyx Biosciences for over $1 billion to enhance its research pipeline in inflammatory bowel disease and neurodegenerative diseases [1] - Amgen (AMGN.US) saw its stock increase by more than 3%, reflecting positive investor sentiment in the obesity drug market [1] - Novo Nordisk (NVO.US) and Pfizer (PFE.US) also experienced stock gains of over 1%, indicating a broader market trend in the sector [1] Analyst Ratings - UBS has maintained a buy rating on Eli Lilly's stock and raised its target price to $1,250, reflecting confidence in the company's growth prospects following the potential acquisition [1]